{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:08:21Z","timestamp":1788775701750,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07536-8","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:17:14Z","timestamp":1788772634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mycophenolate mofetil versus tacrolimus for maintenance of remission in children with frequently relapsing and steroid-dependent nephrotic syndrome: a pilot randomized controlled trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3565-5481","authenticated-orcid":false,"given":"Mohsina","family":"Naj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushik","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-5713","authenticated-orcid":false,"given":"Md Habibullah","family":"Sk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal Kanti","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunansu","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-1365","authenticated-orcid":false,"given":"Avijit","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"7536_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2215\/CJN.00380116","volume":"11","author":"THM Banh","year":"2016","unstructured":"Banh THM, Hussain-Shamsy N, Patel V, Vasilevska-Ristovska J, Borges K, Sibbald C et al (2016) Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 11:1760\u20131768. https:\/\/doi.org\/10.2215\/CJN.00380116","journal-title":"Clin J Am Soc Nephrol"},{"key":"7536_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"key":"7536_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ki.1978.23","volume":"13","author":"International Study of Kidney Disease in Children","year":"1978","unstructured":"International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159\u2013165. https:\/\/doi.org\/10.1038\/ki.1978.23","journal-title":"Kidney Int"},{"key":"7536_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"7536_CR5","doi-asserted-by":"publisher","unstructured":"(1981) Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 20:765\u2013771. https:\/\/doi.org\/10.1038\/ki.1981.209","DOI":"10.1038\/ki.1981.209"},{"key":"7536_CR6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-029249","volume":"148","author":"F Veltkamp","year":"2021","unstructured":"Veltkamp F, Rensma LR, Bouts AHM (2021) Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148:e2020029249. https:\/\/doi.org\/10.1542\/peds.2020-029249","journal-title":"Pediatrics"},{"key":"7536_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769\u2013776. https:\/\/doi.org\/10.1681\/ASN.V85769","journal-title":"J Am Soc Nephrol"},{"key":"7536_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf381","volume":"19","author":"E Frangou","year":"2026","unstructured":"Frangou E, Kronbichler A, Steiger S, Bruchfeld A, Caravaca-Font\u00e1n F, Mirioglu S et al (2026) The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group. Clin Kidney J 19:sfaf381. https:\/\/doi.org\/10.1093\/ckj\/sfaf381","journal-title":"Clin Kidney J"},{"key":"7536_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106526","volume":"11","author":"EYhin Chan","year":"2026","unstructured":"Chan EYhin, Au CT, Yu ELm, Angeletti A, Arslan Z, Boyer O et al (2026) Efficacy and safety of rituximab therapy to sustain remission in young children with childhood nephrotic syndrome. Kidney Int Rep 11:106526. https:\/\/doi.org\/10.1016\/j.ekir.2026.106526","journal-title":"Kidney Int Rep"},{"key":"7536_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","volume":"22","author":"S Fujinaga","year":"2007","unstructured":"Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y et al (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71\u201376. https:\/\/doi.org\/10.1007\/s00467-006-0294-0","journal-title":"Pediatr Nephrol"},{"key":"7536_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","volume":"42","author":"A Bagga","year":"2003","unstructured":"Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114\u20131120. https:\/\/doi.org\/10.1053\/j.ajkd.2003.08.011","journal-title":"Am J Kidney Dis"},{"key":"7536_CR12","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","volume":"22","author":"K Afzal","year":"2007","unstructured":"Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:2059\u20132065. https:\/\/doi.org\/10.1007\/s00467-007-0617-9","journal-title":"Pediatr Nephrol"},{"key":"7536_CR13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904. https:\/\/doi.org\/10.1542\/peds.2017-1904","journal-title":"Pediatrics"},{"key":"7536_CR14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WCJ, Van Der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020. https:\/\/doi.org\/10.1007\/s00467-008-0899-6","journal-title":"Pediatr Nephrol"},{"key":"7536_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nep.12537","volume":"21","author":"J Wang","year":"2016","unstructured":"Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X et al (2016) Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology (Carlton) 21:21\u201327. https:\/\/doi.org\/10.1111\/nep.12537","journal-title":"Nephrology (Carlton)"},{"key":"7536_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.4103\/1319-2442.338275","volume":"32","author":"S Tun\u00e7ay","year":"2021","unstructured":"Tun\u00e7ay S, Mir S, Hakverdi G (2021) What is the best choice in steroid-dependent nephrotic syndrome: mycophenolate mofetil plus dexamethasone or cyclosporine A. Saudi J Kidney Dis Transpl 32:1019. https:\/\/doi.org\/10.4103\/1319-2442.338275","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"7536_CR17","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, T\u00f6nshoff B, Hoyer P, Querfeld U (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697. https:\/\/doi.org\/10.1681\/ASN.2012121200","journal-title":"J Am Soc Nephrol"},{"key":"7536_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamapediatrics.2025.0765","volume":"179","author":"J Wang","year":"2025","unstructured":"Wang J, Liu F, Yan W, Zhou J, Zhang Y, Rong L et al (2025) Tacrolimus or mycophenolate mofetil for frequently relapsing or steroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 179:722. https:\/\/doi.org\/10.1001\/jamapediatrics.2025.0765","journal-title":"JAMA Pediatr"},{"key":"7536_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/apha.70047","volume":"241","author":"CM Hansen","year":"2025","unstructured":"Hansen CM, Bachmann S, Su M, Budde K, Choi M (2025) Calcineurin inhibitor associated nephrotoxicity in kidney transplantation\u2014a transplant nephrologist\u2019s perspective. Acta Physiol 241:e70047. https:\/\/doi.org\/10.1111\/apha.70047","journal-title":"Acta Physiol"},{"key":"7536_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","volume":"16","author":"TH Westhoff","year":"2007","unstructured":"Westhoff TH, Van Der Giet M (2007) Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs 16:1099\u20131110. https:\/\/doi.org\/10.1517\/13543784.16.7.1099","journal-title":"Expert Opin Investig Drugs"},{"key":"7536_CR21","doi-asserted-by":"publisher","unstructured":"(2011) How do calcineurin inhibitors cause hypertension? Nat Rev Nephrol 7:677. https:\/\/doi.org\/10.1038\/nrneph.2011.165","DOI":"10.1038\/nrneph.2011.165"},{"key":"7536_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fped.2019.00287","volume":"7","author":"IF Shatat","year":"2019","unstructured":"Shatat IF, Becton LJ, Woroniecki RP (2019) Hypertension in childhood nephrotic syndrome. Front Pediatr 7:287. https:\/\/doi.org\/10.3389\/fped.2019.00287","journal-title":"Front Pediatr"},{"key":"7536_CR23","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s00467-024-06375-9","volume":"39","author":"A Maniar","year":"2024","unstructured":"Maniar A, Gipson DS, Brady T, Srivastava T, Selewski DT, Greenbaum LA et al (2024) Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study. Pediatr Nephrol 39:2691\u20132701. https:\/\/doi.org\/10.1007\/s00467-024-06375-9","journal-title":"Pediatr Nephrol"},{"key":"7536_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-026-07292-9","author":"AK M\u00fchlig","year":"2026","unstructured":"M\u00fchlig AK, Hengel FE, Oh J, Tomas NM, Huber TB (2026) Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-026-07292-9","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07536-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:17:15Z","timestamp":1788772635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07536-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":24,"alternative-id":["7536"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07536-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed written consent was obtained from parents or legal guardians of all included participants for publication of anonymous patients\u2019 data.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from all legal guardians before enrolment in the trial.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}